January 23, 2014 15:43 ET
EDMONTON, ALBERTA--(Marketwired - Jan. 23, 2014) - Innovotech Inc. (TSX VENTURE:IOT) ("Innovotech") today announced that, in accordance with the policies of the TSX Venture Exchange, the board of directors has approved a grant of stock options to management of Innovotech to purchase 50,000 common shares pursuant to its stock option plan. These options have an exercise price of $0.045 per common share and expire on January 22, 2024.
About Innovotech Inc:
Innovotech Inc. is an innovator in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.
Innovotech has a range of products that address the issue of biofilms within a number of different industries, including commercially available products in a variety of market segments; the MBEC Assay™, InnovoSIL™, bioFILM PA™, InnovoSCEPT™-Human and InnovoSCEPT™-Veterinary tests. The MBEC Assay™ is a high throughput biofilm growth device that is an ASTM International standard. InnovoSIL™ is a family of silver-based antimicrobials promising superior performance for medical device coatings and wound dressings, bioFILM PA™ and InnovoSCEPT™-Human are the first diagnostic tests to assist physicians in the selection of the most effective antibiotic treatment for patients with biofilm-based chronic infections, while the InnovoSCEPT™-Veterinary tests are designed to determine the most effective antibiotic treatment for chronic infections in both large and small animals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Innovotech Inc.Dr. James TimourianPresident780.448.0585 ext email@example.com
See all RSS Newsfeeds